Data from the phase 3 POSEIDON trial support the use of tremelimumab, durvalumab, and chemotherapy for patients with metastatic non–small cell lung cancer, including harder-to-treat subgroups, in the first-line.
Updated findings from the phase 3 POSEIDON trial (NCT03164616) support the use of tremelimumab (Imjudo), durvalumab (Darzalex), and chemotherapy as a first-line combination approach vs chemotherapy alone in patients with metastatic non–small cell lung cancer, including harder-to-treat subgroups. Results included analyses by nonsquamous or squamous histology, and by STK11, KEAP1, or KRAS mutational status for mutation-positive or wild type disease. The -year follow-up data were presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023 by Solange Peters, MD, PhD.
“After a median follow-up of more than 5 years, [POSEIDON] demonstrated a durable long-term overall survival [OS] benefit [when] adding a limited course of tremelimumab and durvalumab,” said Peters, professor and chair of the Medical Oncology and Thoracic Malignancies Programme, Department of Oncology, University Hospital of Lausanne, Switzerland. “The 5-year [OS] rate [for the triplet] was more than twice as high than chemotherapy, 15.7% vs 6.8%,” Peters continued.
In POSEIDON, 1013 patients were randomly assigned to 3 arms: tremelimumab plus durvalumab plus chemotherapy (arm 1); durvalumab plus chemotherapy (arm 2); or chemotherapy alone arm (arm 3). The dosing schedule was every 3 weeks for 4 cycles, every 3 weeks for 4 cycles, and every 3 weeks for up 6 to cycles, respectively. Patients in arm 1 received tremelimumab at week 16 only and durvalumab every 4 weeks until disease progression. Patients in arm 2 received durvalumab every 4 weeks until disease progression.
Eligible patients had an ECOG performance status 0 or 1, had EGFR or ALK wild type, and were treatment naive for metastatic disease. “ Patients were stratified according to PD-L1 expression, disease stage, and histology,” Peters said. “Prespecified long-term follow-up end points included [OS] and serious adverse events [AEs],” she added.
Investigators noted that long-term OS benefit comparing the triplet combination vs chemotherapy alone showed a greater benefit in patients with nonsquamous histology with an HR of 0.69 and 5-year OS rates of 20.5% vs 9.1%.
In the mutation-evaluable population, 30% had a KRAS mutation (n = 37), 6% had a KEAP1 mutation (n = 37) , and had a STK11 mutation (n = 87).
The updated OS by STK11 mutation showed that patients treated with the triplet regimen had a median OS of 15.0 months (HR, 0.57; 95% CI, 0.32-1.04) compared with 6.9 months for patients treated with durvalumab and chemotherapy (HR, 1.02; 95% CI, 0.59-1.80) and 10.7 months with patients treated with chemotherapy only (95% CI, 6.0-14.9). The OS benefit was maintained for the triplet regimen in patients with STK11 mutation with an HR of 0.57 and 5-year OS rates of 12.9% vs 0% for the chemotherapy regimen.
The updated OS by KEAP1 mutation status across all histologies showed that the OS benefit was maintained for the triplet regimen with an HR of 0.43. In patients with the KEAP1 mutation, patients who were treated with the triplet had a median OS of 13.7 months (HR, 0.43; 95% CI, 0.16-1.25), patients treated with the doublet had a median OS of 8.1 months (HR, 0.77; 95% CI, 0.31-2.15), and patients treated with chemotherapy had a median OS of only 8.7 months.
In patients with KRAS mutations, the OS benefit maintained for the triplet regimen vs chemotherapy alone led to an OS of 0.55 and a 5-year OS rate of 21.7% vs 8.1%, respectively.
The TABLE1 shows subsequent systemic anticancer therapy by regimen arm. "In the chemotherapy alone arm, 63% of the patients received subsequent immunotherapy vs more or less [than] in the immunotherapy arms subsequently,” Peters said.
Serious adverse events (SAEs), including AEs leading to death, were collected during long-term follow-up. No other safety data were collected after the final analysis for OS superiority. Since the final analysis, 7 additional patients experienced SAEs (1 considered to be treatment related) and 4 additional patients had AEs leading to death (none were treatment related).
“Across patient subgroups, long-term OS benefit was generally consistent with the intention-to-treat population,” Peters said. “ Consistent with earlier analysis, the addition of tremelimumab to durvalumab and chemotherapy provided OS benefit regardless of PD-L1 expression,” concluded Peters.
Overcoming Barriers in Cancer Clinical Trials: A Path Forward for Better Patient Care
April 29th 2024Clinical trials play a pivotal role in developing effective therapies, yet their integration is challenged by issues such as insufficient reimbursement structures, misaligned incentives, physician burnout, and a complex regulatory environment.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More